阿拉丁(688179.SH):擬投建阿拉丁藥用科研試劑創新研發與生產基地項目
格隆匯8月3日丨阿拉丁(688179.SH)公佈,根據公司中長期戰略發展規劃及未來市場需求,公司於2022年8月3日召開第三屆董事會第三十一次會議及第三屆監事會第二十六次會議,審議通過《關於投資建設阿拉丁藥用科研試劑創新研發與生產基地項目的議案》,公司擬以自有資金及自籌資金人民幣4.00億元用於項目建設。
阿拉丁藥用科研試劑創新研發與生產基地項目主要集中於藥用科研試劑的開發,包括藥用科研試劑反應技術及其合成工藝的研究開發;高純科研試劑盒的研究開發;活性功能性生物試劑的研究開發。通過開發基地的建立和運行增強公司藥用科研試劑產品的研發與生產能力,提升公司綜合競爭力。
項目預選址位於上海杭州灣經濟技術開發區節餘地塊,地塊名稱為市化工區奉賢分區A14-04地塊,項目用地使用年限為35年(具體以土地出讓合同為準),主要建設廠房、研發大樓、辦公樓、倉庫和其他配套設施。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.